New vaccine approaches for seasonal and pandemic influenza

Vaccine

Volumn 26, Issue 49, 2008, Pages 6232-6236

  Palache, Bram ^a  

^a Solvay Biologicals BV   (Netherlands)

Author keywords

(Pre )pandemic influenza vaccine; Influenza vaccine research methodology; Seasonal influenza vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

ARTICLE; DRUG EFFICACY; EPIDEMIC; HUMAN; INFLUENZA; INFLUENZA VACCINATION; PANDEMIC; PRIORITY JOURNAL;

ANIMALS; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; SEASONS; VACCINES, INACTIVATED;

EID: 55249105905     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.022     Document Type: Article

References (66)

1. IFPMA. Influenza vaccine supply international task force. Technical briefing for WHO intergovernmental meeting on sharing of influenza viruses and access to vaccines and other benefits; November 20, 2007. http://www.ifpma.org/Influenza/content/pdfs/2007_11_20_IFPMA_IVS_Contributions_and_Commitments.pdf [accessed April 5, 2008].
2. Ryan J., Zoellner Y., Gradl B., Palache B., and Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24 (2006) 6812-6822
3. World Health Organization. World Health Organization 56th World Health Assembly-prevention and control of influenza pandemics and annual epidemics (2003), World Health Organization, Geneva
4. Szucs T. Seasonal influenza vaccination in Europe; 2006/2007 coverage rates in 11 European countries; 2007. http://www.evm-vaccines.org/pdfs/ep_071003_presentation.pdf [accessed April 5, 2008].
5. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 333 (2006) 912-915
6. Jackson L.A., Nelson J.C., Benson P., Neuzil K.M., Reid R.J., Psaty B.M., et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 35 (2006) 345-352
7. Simonsen L., Taylor R.J., Viboud C., Miller M.A., and Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 7 (2007) 658-666
8. Fedson D.S., and Nichol K.L. Influenza vaccination: policy versus evidence: no gap between policy and evidence [letter]. BMJ 333 (2006) 1020
9. Jackson L.A., Jackson M.L., Nelson J.C., Neuzil K.M., and Weiss N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35 (2006) 337-344
10. Nichol Kl. Some challenges and pitfalls in the interpretation of systematic reviews of influenza vaccine efficacy and effectiveness. The European Scientific Working Group Influenza on Influenza. The Influenza Bulletin no. 22; 2007. http://www.eswi.org/myUploadData/files/ESWI_bulletin_22.pdf:4-5 [accessed April 5, 2008].
11. Belongia E.A., Coleman L.A., and Donahue J.G. Effectiveness of influenza vaccination [letter]. N Engl J Med 357 (2007) 2728
12. Nelson J.C., Jackson M.L., and Jackson L.A. Effectiveness of influenza vaccination [letter]. N Engl J Med 357 (2007) 2728-2729
13. Simonsen L., Viboud C., and Taylor R.J. Effectiveness of influenza vaccination [letter]. N Engl J Med 357 (2007) 2729-2730
14. Braun M.M., Izurieta H.S., and Ball R. Effectiveness of influenza vaccination [letter]. N Engl J Med 357 (2007) 2730
15. Nichol K.L., Nordin J.D., and Hak E. Effectiveness of influenza vaccination [letter]. N Engl J Med 357 (2007) 2730-2731
16. Committee for Medicinal Products for Human Use. Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. Issued March 12, 1997. http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf [accessed April 5, 2008].
17. Beyer W.E., Palache A.M., Lüchters G., Nauta J., and Osterhaus A.D. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res 103 (2004) 125-132
18. Nauta J.J., and de Bruijn I.A. The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals. Vaccine 24 (2006) 6643-6644
19. Potter C.W. Chronicle of influenza pandemics. In: Nicholson K.G., Webster R.G., and Hay A.J. (Eds). Textbook of influenza (1998), Blackwell Science Ltd., Oxford 3-18
20. Francis T.J. Vaccination against influenza. Bull World Health Organ 8 (1953) 725-741
21. Davenport F.M., Hennessy A.V., Brandon F.M., Webster R.G., Barrett C.D., and Leese G.O. Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins. J Lab Clin Med 63 (1964) 5-13
22. Bachmayer H., Liehl E., and Schmidt G. Preparation and properties of a novel influenza subunit vaccine. Postgrad Med J 52 (1976) 360-367
23. Brady M.I., and Furminger I.G.S. A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins. J Hyg (Lond) 77 (1976) 161-172
24. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 56 RR 6 (2007) 1-54
25. Wood J.M. Standardization of inactivated influenza vaccines. In: Nicholson K.G., Webster R.G., and Hay A. (Eds). Textbook of influenza (1998), Blackwell Science Ltd., Oxford 333-345
26. Beyer W.E.P., and Palache A.M. Osterhaus ADME. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus pr split virus vaccines. A review and meta-analysis of the literature. Clin Drug Invest 15 (1998) 1-12
27. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., and Cryz S.J.J. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344 (1994) 160-163
28. Ott G., Barchfeld G.L., and Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13 (1995) 1557-1562
29. Moss P. Cellular immune responses to influenza. Dev Biol (Basel) 115 (2003) 31-37
30. Moldoveanu Z., Clements M.L., Prince S.J., Murphy B.R., and Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 13 (1995) 1006-1012
31. Johansson B.E., and Brett I.C. Changing perspective on immunization against influenza. Vaccine 25 (2007) 3062-3065
32. Stephenson I., Gaines Das R., Wood J.M., and Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25 (2007) 4056-4063
33. Nicholson K.G., Kent J., Hammersley V., and Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 315 (1997) 1060-1064
34. Demicheli V., Jefferson T., Rivetti D., and Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 18 (2000) 957-1030
35. Villari P., Manzoli L., and Boccia A. Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. Vaccine 22 (2004) 3475-3486
36. Avorn J. In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 357 (2007) 19-21
37. Nichol K.L., and Mendelman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Res 103 (2004) 3-8
38. Beyer W.E.P. Heterogeneity of case definitions used in vaccine effectiveness studies-and its impact on meta-analysis. Vaccine 24 (2006) 6602-6604
39. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 (2003) 1769-1775
40. Jefferson T.O., Rivetti D., Di Pietrantonj C., Rivetti A., and Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 4 (1999) CD001269 10.1002/14651858.CD001269.pub3
41. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., and Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366 (2005) 1165-1174
42. Nichol K.L. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 161 (2001) 749-759
43. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 75 (2000) 281-288
44. Fedson D.S. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prev Med 23 (1994) 751-755
45. World Health Organization. Global pandemic influenza action plan to increase vaccine supply; 2006. http://www.who.int/vaccines-documents/DocsPDF06/863.pdf [accessed April 5, 2008].
46. Fiers W., De Filette M., Birkett A., Neirynck S., and Min Jou W. A "universal" human influenza A vaccine. Virus Res 103 (2004) 173-176
47. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356 (2007) 685-696
48. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350 (2004) 896-903
49. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B., et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15 (1997) 1675-1679
50. Ruf B.R., Colberg K., Frick M., and Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32 (2004) 191-198
51. de Bruijn I.A., Meyer I., Gerez L., Nauta J.N., Giezeman K., and Palache A.M. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 26 (2007) 119-127
52. Pharmaprojects. EU filing for Sanofi Pasteur's intradermal 'flu vaccine; February 22, 2008 http://www.pharmaprojects.com/news/2202_1429.htm [accessed April 5, 2008].
53. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 (2004) 2286-2294
54. Belshe R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25 (2007) 6755-6763
55. IFPMA. Influenza vaccine supply international task force. R&D for avian/pandemic influenza vaccines by IFPMA Influenza Vaccine Supply International Task Force (IVS ITF) members. Updated October 17, 2006. http://www.ifpma.org/Influenza/content/pdfs/Table_Avian_Pandemic_Influenza_RnD_17Oct06.pdf [accessed April 5, 2008].
56. Anon. GSK wins EMEA approval for pandemic vaccine. http://www.fiercebiotech.com/story/gsk-wins-emea-approval-for-pandemic-vaccine/2006-12-15 [accessed April 5, 2008].
57. Anon. EMEA recommends authorisation of first pre-pandemic influenza vaccine, Europe. http://www.medicalnewstoday.com/articles/98295.php [accessed April 5, 2008].
58. Anon. New pandemic flu vaccine gets EU approval. http://www.in-pharmatechnologist.com/news/ng.asp?id=76379-novartis-emea-influenza-pandemic-vaccine [accessed April 5, 2008].
59. Palache A.M., Brands R., and van Scharrenburg G.J. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 176 Suppl. 1 (1997) S20-S23
60. Kistner O., Howard M.K., Spruth M., Wodal W., Brühl P., Gerencer M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25 (2007) 6028-6036
61. Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008; March 6 [Epub ahead of print].
62. Pau M.G., Ophorst C., Koldijk M.H., Schouten G., Mehtali M., and Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19 (2001) 2716-2721
63. Cox M.M. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 10 (2008) 56-61
64. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363 (2004) 587-593
65. Aballéa S., Chancellor J., Martin M., Wutzler P., Carrant F., Gasparini R., et al. The cost-effectiveness of influenza vaccination for people aged 50-64 years: an international model. Value Health 10 (2007) 98-116
66. Skinner G.R. Nice work for everybody except the patient. Vaccine 7 (1989) 382-384